Supplementary material to article by S. Sherman et al. "Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population"

Table SI. Demographic details of patients with melanoma

Characteristics	Mycosis fungoides $(n = 47)$	Psoriasis $(n = 23)$	<i>p</i> -valu
Sex, n (%)			0.019
Male	33 (70.2)	9 (39.1)	
Female	14 (29.8)	14 (60.9)	
Fitzpatrick skin type, <i>n</i>			0.934
1	3	1	
2	14	4	
3	8	2	
4	3	1	
Unknown	19	15	
Outdoor occupation, n (%)			0.635
No	18 (38.3)	7 (30.4)	
Yes	6 (12.8)	2 (8.7)	
Unknown	23 (48.9)	14 (60.9)	
Country of origin, <i>n</i> (%)			0.052
Europe	26 (55.3)	11 (47.8)	
Other ^b	14 (29.8)	3 (13.1)	
Israel	7 (14.9)	9 (39.1)	
Area of residence, n (%)			0.708
Urban	40 (85.1)	21 (91.3)	
Rural	7 (14.9)	2 (8.7)	
Family history of melanoma, n (%)	. ,	. ,	0.213
Yes	21 (44.7)	3 (13.0)	
No	9 (19.1)	4 (17.4)	
Unknown	17 (36.2)	16 (69.6)	
Age at MF/psoriasis diagnosis, years, mean \pm SD	57.8 ± 15.4	53.1 ± 18.8	0.268
Age at melanoma diagnosis, years, mean±SD	58.6±13.7	55.0 ± 15.1	0.287
Age groups, n			
0-40 years	4	2	0.335
40-60 years	19	13	
> 60 years	24	8	
Age at end of study, years, mean ± SD	68.6±12.7	66.7±14.1	0.571
First diagnosis, n (%)			1.0
Mycosis fungoides/psoriasis	28 (59.6)	14 (60.9)	
Melanoma	19 (40.4)	9 (39.1)	
Follow-up period to melanoma diagnosis, years, median (range) ^a	5.5 (1-30)	7.0 (1-50)	0.728
Phototherapy status ^a , n (%)		()	
No phototherapy	10 (35.7)	10 (76.9)	
After phototherapy	18 (64.3)	3 (23.1)	0.057
Phototherapy type, n	10 (01.3)	5 (25.1)	0.037
NB-UVB	13	2	
Systemic PUVA	1	0	
NB-UVB+PUVA (seq)	4	1	
Immunosuppressive and DNA-damaging treatments ^a	3	3	0.383
Total skin electron beam, n	1	5	0.505
Methotrexate, n	1	2	
Tumour necrosis factor alpha inhibitors, <i>n</i>		2	
Topical nitrogen mustard, n	2	T	
Other malignancies, <i>n</i>	2	13	0.667
Non-melanoma skin cancer, <i>n</i>	13	7	0.007
	2	1	
Lymphoid malignancies, n Brasst sansor, n	2	1	
Breast cancer, n	=	-	
Lung cancer, n	2	0	
Bladder cancer, n	2	0	
Colon cancer, n	1	1	
Prostate cancer, n	1	1	
Parotid gland cancer, n	1	1	

^aExcluding patients with prior melanoma. ^bOther: North Africa, Central and South America and Middle East. SD: standard deviation; NB-UVB: narrow-band ultraviolet B; PUVA: psoralen and ultraviolet A; seq: sequential.